OUR MISSION~ to develop molecules that can selectively

bind to mitochondrial DNA mutations that are implicated as causative for several progressive neurological and other degenerative disorders-addressing one of medicine’s most intractable challenges.

Our mandate is precise: intervene at the genetic origin of disease,

not merely palliate its symptoms.

Under the leadership of Drs. Glenn  Burley and Simon McKay –

of the University of Strathclyde’s Pure and Applied Chemistry department, an internationally recognized team with more than

60 combined years in novel DNA-targeted synthetic chemistries –

we can transform the complexity of mitochondrial biology into clinically actionable breakthroughs, leveraging unrivaled expertise

in mitochondrial genomics and cell-based assay innovation.

Our integrated UK-US scientific teams have developed first-in-class compounds with unprecedented selectivity for mitochondrial

DNA binding and precisely defined molecular mechanisms of

action. This is next-generation mitochondrial medicine-pushing

the boundaries of neuro and bioscience and transforming the treatment paradigm for degenerative diseases by intervening

at their genetic source.